Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Argus Health
Express Scripts
Citi
Harvard Business School
Boehringer Ingelheim
McKesson
Chinese Patent Office
McKinsey

Generated: April 26, 2018

DrugPatentWatch Database Preview

LAMPRENE Drug Profile

« Back to Dashboard

When do Lamprene patents expire, and what generic alternatives are available?

Lamprene is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in LAMPRENE is clofazimine. There are four drug master file entries for this compound. Additional details are available on the clofazimine profile page.
Drug patent expirations by year for LAMPRENE
Medical Subject Heading (MeSH) Categories for LAMPRENE
Synonyms for LAMPRENE
(3E)-N,5-bis(4-chlorophenyl)-3-isopropylimino-phenazin-2-amine
(3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine
(4-Chloro-phenyl)-[5-(4-chloro-phenyl)-3-isopropylimino-3,5-dihydro-phenazin-2-yl]-amine
(4-chlorophenyl)[5-(4-chlorophenyl)-3-(2-methyl-1-azapropylidene)(5-hydrophena zin-2-yl)]amine
(E)-N,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine
(non-d)Clofazimine-d7
030C639
2-p-Chloranilino-5-p-chlorphenyl-3,5-dihydro-3-isopropylimino-phenazin
2-p-chloroanilino-5-p-chlorophenyl-3,5-dihydro-3-isopropyliminophenazine
2-Phenazinamine, 3,5-dihydro-N,5-bis(4-chlorophenyl)-3-((1-methylethyl)imino)-
2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-
2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-
2-Phenazinamine,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-
2-Phenazinamine,5-dihydro-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-
2030-63-9
3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine
3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine
3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin
3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]
3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine
4-25-00-03033 (Beilstein Handbook Reference)
A814428
AC1L1EHE
AKOS015896438
AKOS026749881
AN-16626
B 663
B 663 (Pharmaceutical)
B 663 (VAN)
B 663, pharmaceutical
B-663
B. 663
B663
BDBM50318909
BDBM50378783
BIDD:PXR0147
BPBio1_000585
BRN 0060420
BSPBio_000531
C06915
C27H22Cl2N4
CAS-2030-63-9
CCG-101159
CFZ
CHEBI:3749
CHEMBL1083384
CHEMBL1292
CHEMBL1369407
Chlofazimine
cid_2794
Clofazimin
Clofazimina
Clofazimina [INN-Spanish]
clofazimine
Clofazimine (JAN/USP/INN)
Clofazimine [USAN:INN:BAN]
Clofazimine [USAN:USP:INN:BAN]
Clofazimine for system suitability, European Pharmacopoeia (EP) Reference Standard
Clofazimine, European Pharmacopoeia (EP) Reference Standard
Clofazimine, United States Pharmacopeia (USP) Reference Standard
Clofaziminum
Clofaziminum [INN-Latin]
CPD000058704
CS-4567
CTK6H0611
D00278
D07NPR
D0S5UH
D959AE5USF
DB00845
DSSTox_CID_2839
DSSTox_GSID_22839
DSSTox_RID_76752
DTXSID7022839
EINECS 217-980-2
FT-0657414
G 30320
G-30,320
G-30320
GTPL9184
HMS1569K13
HMS2052B05
HMS2093J10
HMS2096K13
HMS2231B04
HMS3370N05
HMS3394B05
HMS3652A16
HY-B1046
I06-1891
J-013203
KS-00000XN9
KS-1412
KSC-27-052A
KUC109573N
Lampren
Lamprene (TN)
Liposome-encapsulated clofazimine
LS-103014
MCULE-1387160272
MFCD00056793
MLS000028617
MLS001424318
MLS006010789
MMV687800
MolPort-003-940-861
MolPort-042-621-745
N,5-Bis(4-chlorophenyl)-3-([1-methylethyl]imino)-3,5-dihydro-2-phenazinamine #
N,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine
N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine
N,5-bis(4-chlorophenyl)-3-[(propan-2-yl)imino]-3,5-dihydrophenazin-2-amine
N,5-bis(4-chlorophenyl)-3-isopropylimino-phenazin-2-amine
N,5-bis(4-chlorophenyl)-3-propan-2-ylimino-2-phenazinamine
N,5-bis(4-chlorophenyl)-3-propan-2-ylimino-phenazin-2-amine
N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine
N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine
N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropyliaino)phenazin-2-amine
N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine
N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine
NC00409
NCGC00016600-01
NCGC00016600-02
NCGC00016600-03
NCGC00016600-04
NCGC00016600-05
NCGC00016600-07
NCGC00179529-01
NSC 141046
NSC-141046
NSC-759283
NSC141046
NSC759283
Pharmakon1600-01505974
Phenazine, 2,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-
Phenazine, 3-(p-chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-
Phenazine,10-dihydro-2-(isopropylimino)-
Phenazine,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-
PL002217
PL049918
Prestwick_685
Prestwick0_000376
Prestwick1_000376
Prestwick2_000376
Prestwick3_000376
Riminophenazine
Riminophenazine (tuberculosis infection)
Riminophenazine (tuberculosis infection), TB Alliance/IMM/BTTTRI/University of Illinois
Riminophenazines (Mycobacterium tuberculosis infection), The Global Alliance for TB Drug Development/Institute of Materia Medica
s4107
SAM001246878
SBI-0206865.P001
SC-47057
SCHEMBL26757
SCHEMBL26758
SCHEMBL5663361
SMP2_000339
SMR000058704
SMR004701474
SPBio_002452
SR-05000001807
SR-05000001807-2
ST51014966
Tox21_110516
UNII-D959AE5USF
WDQPAMHFFCXSNU-KRUMMXJUSA-N
Z2037279473
Z3118
ZINC100037101
ZINC17953024
ZINC253916263

US Patents and Regulatory Information for LAMPRENE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis LAMPRENE clofazimine CAPSULE;ORAL 019500-002 Dec 15, 1986 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis LAMPRENE clofazimine CAPSULE;ORAL 019500-001 Dec 15, 1986 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Accenture
McKesson
Johnson and Johnson
Healthtrust
Deloitte
Queensland Health
US Department of Justice
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.